Androgen biosynthesis in the human fetus proceeds through the adrenal sex steroid precursor dehydroepiandrosterone, which is converted to testosterone in the gonads, followed by further activation to ...

Credit: Shutterstock. Crinecerfort is an investigational, oral, selective corticotropin-releasing factor type 1 receptor (CRF1) antagonist. A phase 3 study evaluating the efficacy and safety of ...

Share on Facebook. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window BOSTON -- Investigational crinecerfont reduced the need for ...

Please provide your email address to receive an email when new articles are posted on . Crinecerfont was granted FDA breakthrough therapy designation for the treatment of congenital adrenal ...

The US Food and Drug Administration has approved crinecerfont (Crenessity) for use in combination with glucocorticoids in the treatment of adults and children aged 4 years or older with classic ...

Congenital adrenal hyperplasia (CAH) represents a group of inherited disorders resulting from enzyme deficiencies that disrupt the synthesis of adrenal steroid hormones. One notable form, caused by ...

Orlando, Florida — New data add to the evidence supporting use of crinecerfont for the treatment of congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency, in both adults and children.

Phyllis Speiser is emeritus professor of pediatrics at Zucker School of Medicine at Hofstra-Northwell and associate investigator at The Feinstein Institute for Medical Research of Northwell Health.

Nonclassical congenital adrenal hyperplasia (NCAH) can lead to the production of excess male hormones. It is usually a mild condition and often doesn’t need to be treated. Nonclassical congenital ...

Management of classic congenital adrenal hyperplasia (CAH) can be a lifelong balancing act, but the most feared life-threatening complication is an acute adrenal insufficiency, also known as an ...